Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

Polack FP et al.N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.

Thomas SJ et al.N Engl J Med. 2021 Nov 4;385(19):1761-1773. doi: 10.1056/NEJMoa2110345. Epub 2021 Sep 15.

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.

Frenck RW Jr et al.N Engl J Med. 2021 Jul 15;385(3):239-250. doi: 10.1056/NEJMoa2107456. Epub 2021 May 27.

One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series.

Cramer JP¹, Jelinek T², Paulke-Korinek M³, Reisinger EC⁴, Dieckmann S⁵, Alberer M⁶, Bühler S⁷, Bosse D⁸, Meyer S⁸, Fragapane E⁹, Costantini M⁹,Pellegrini M¹⁰, Lattanzi M⁹, Dovali C⁹.

Serological response following re-vaccination with Salmonella typhi Vi-capsular polysaccharide vaccines in healthy adult travellers.

Roggelin L¹, Vinnemeier CD², Fischer-Herr J³, Johnson-Weaver BT⁴, Rolling T⁵, Burchard GD⁶, Staats HF⁷, Cramer JP⁸.

A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.

Roggelin L^1,2, Vinnemeier CD^1,2, Meyer S³, Witte K³, Marx L^2,4, Theeß W², Burchard GD^1,2, Rolling T^1,2, Cramer JP^1,2.

Evaluation of rabies immunogenicity and tolerability following a purified chick embryo cell rabies vaccine administered concomitantly with a Japanese encephalitis vaccine.

Jelinek T¹, Cramer JP², Dieckmann S³, Hatz C⁴, Paulke-Korinek M⁵, Alberer M⁶, Reisinger EC⁷, Costantini M⁸, Gniel D⁹, Bosse D⁹, Lattanzi M¹⁰.

Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala.

Behrens RH¹, Cramer JP², Jelinek T³, Shaw H⁴, von Sonnenburg F⁵, Wilbraham D⁶, Weinke T⁷, Bell DJ⁸, Asturias E⁹, Pauwells HL¹⁰, Maxwell R¹¹, Paredes-Paredes M¹², Glenn GM¹³, Dewasthaly S¹⁴, Stablein DM¹⁵, Jiang ZD¹⁶, DuPont HL¹⁷.

Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study.

Vinnemeier CD¹, Fischer-Herr J¹, Meyer S², Liebig K², Theeß W³, Burchard GD¹, Cramer JP¹.

Efficacy of a travelers' diarrhea vaccine system in travelers to India.

Steffen R¹, Cramer JP, Burchard G, Jelinek T, Schwarz U, Ramdas P, Chatterjee S, Jiang ZD, DuPont HL, Dewasthaly S, Westritschnig K, Behrens RH.

Clinical relevance of different biomarkers in imported plasmodium falciparum malaria in adults: a case control study.

Stauga S¹, Hahn A, Brattig NW, Fischer-Herr J, Baldus S, Burchard GD, Cramer JP.

A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations.

Hatz C¹, Cramer JP, Vertruyen A, Schwarz TF, von Sonnenburg F, Borkowski A, Lattanzi M, Hilbert AK, Cioppa GD, Leroux-Roels G.

Influenza A(H1N1)pdm09 antibodies after pandemic and trivalent seasonal influenza vaccination as well as natural infection in November 2010 in Hamburg, Germany.

Cramer J¹, Mac T, Hogan B, Stauga S, Eberhardt S, Wichmann O, Mertens T, Burchard G.

Reduced cardiac output in imported Plasmodium falciparum malaria.

Herr J¹, Mehrfar P, Schmiedel S, Wichmann D, Brattig NW, Burchard GD, Cramer JP.

Short-Term Immunogenicity and Safety of an Accelerated Pre-Exposure Prophylaxis Regimen With Japanese Encephalitis Vaccine in Combination With a Rabies Vaccine: A Phase III, Multicenter, Observer-Blind Study.

Jelinek T¹, Burchard GD², Dieckmann S³, Bühler S⁴, Paulke-Korinek M⁵, Nothdurft HD⁶, Reisinger E⁷, Ahmed K⁸, Bosse D⁹, Meyer S⁹, Costantini M¹⁰,Pellegrini M¹⁰.